U.S. Stock Market Movement: Definium surged on October 9 as JPMorgan issued its first rating and DT120 Phase III releases
Bitget异动解读2026/10/09 15:40Definium October 9th Surge Interpretation
Keywords: JPMorgan's First Coverage, DT120 Phase III
1. On October 9th, JPMorgan covered Definium for the first time, assigning an “Overweight” rating with a target price of $84. According to information, the company’s stock has an average rating of Buy and an average target price of $65.69.
2. On September 14th, the company announced that DT120 met the primary and all key secondary endpoints in the Panorama Phase III study for generalized anxiety disorder. The 100mcg dose demonstrated a HAM-A placebo-adjusted improvement of 5.1 points at week 12 (p<0.0001), with no new safety signals identified. The company plans to engage with regulators in Q4 2026 and submit a marketing application in the first half of 2027.
3. As of June 30th, the company held approximately $1.1 billion in cash, cash equivalents, and investments. Its main business is developing next-generation therapies for psychiatric and neurological disorders, with core candidates including DT120 and DT402, providing a financial foundation for clinical development and regulatory progress.
(Disclaimer: This content was compiled by AI technology summarizing publicly available information. For reference only and does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cross-chain atomic transactions between Ethereum mainnet and L2
US Stock Movement | US clinical-stage biopharmaceutical company Retension Pharmaceuticals (RTSN.US) enters the US stock market, shares drop over 10% after opening
According to Jinse Finance, Retension Pharmaceuticals (RTSN.US) debuted on the US stock market on Friday and fell over 10% to $10.77 at press time, with an IPO price of $12. Retension Pharmaceuticals is a US-based clinical-stage biopharmaceutical company focused on developing innovative drugs for the treatment of hypertension and other cardiovascular diseases. The company's core investigational drug, RTN-001, is a new generation phosphodiesterase 5 (PDE5) inhibitor, primarily targeting patients with uncontrolled or resistant hypertension, and is currently undergoing a Phase IIb clinical trial. This drug works by enhancing nitric oxide signaling in blood vessels to promote vasodilation and lower blood pressure. The exclusive global development license comes from French pharmaceutical giant Sanofi (SNY.US).
Crypto prices
More
